Detalhe da pesquisa
1.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
Blood
; 141(17): 2047-2061, 2023 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36724453
2.
Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML.
Blood
; 139(8): 1208-1221, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34482403
3.
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
Am J Hematol
; 99(2): E32-E36, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37994196
4.
Functional genomic landscape of acute myeloid leukaemia.
Nature
; 562(7728): 526-531, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30333627
5.
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Cancer
; 129(15): 2308-2320, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078412
6.
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
Ann Hematol
; 102(4): 749-754, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36732419
7.
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
Am J Hematol
; 98(2): 272-281, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36309981
8.
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.
J Natl Compr Canc Netw
; 20(2): 106-117, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35130502
9.
Novel Approaches for Systemic Mastocytosis.
Curr Opin Hematol
; 26(2): 112-118, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30694839
10.
How we diagnose and treat systemic mastocytosis in adults.
Br J Haematol
; 180(1): 11-23, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29048112
11.
Implementing a comprehensive translational oncology platform: from molecular testing to actionability.
J Transl Med
; 16(1): 358, 2018 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30551737
12.
Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
Ann Hematol
; 102(8): 2299, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37341779
13.
Nonbiological factors affecting survival in younger patients with acute myeloid leukemia.
Cancer
; 121(21): 3877-84, 2015 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26367383
14.
Applicability of the AML knowledge bank approach.
Blood
; 132(8): 775-776, 2018 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30139831
15.
Acute Lymphoblastic Leukemia, Version 2.2015.
J Natl Compr Canc Netw
; 13(10): 1240-79, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26483064
16.
Myelodysplastic syndromes, version 2.2015.
J Natl Compr Canc Netw
; 13(3): 261-72, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25736003
17.
Therapy-related B-lymphoblastic leukemia associated with Philadelphia chromosome and MLL rearrangement: Single institution experience and the review of the literature.
Pathol Int
; 65(10): 536-40, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26259760
18.
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
Blood Adv
; 8(6): 1515-1528, 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38290135
19.
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Blood Adv
; 8(2): 429-440, 2024 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37871309
20.
Myelodysplastic syndromes: clinical practice guidelines in oncology.
J Natl Compr Canc Netw
; 11(7): 838-74, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23847220